Collaborations in China

• Established Clinical Research Centers in China with over 200 drug development projects conducted in collaboration with over 30 leading medical universities/hospitals.
• GSK is a clinical research leader in developing medicines for hepatitis, asthma, diabetes, oncology and mood disorders in China.
• Since the early 1990s, GSK has supported long-term antibiotics sensitivity studies in collaboration with leading Chinese microbiologists and clinical specialists.
• In the early 1990s, GSK co-operated with the Chinese Institute of Medical Plants on a screening project involving 10,000 varieties of traditional Chinese herbs.
• Since 1995, GSK has collaborated in the R&D field of genomics. The first project funded two of biomedical research laboratories in the Xiangya Medical University and the Shanghai Second Medical University/Ruijin Hospital.
• Since 1997, GSK has collaborated in the field of combinatorial chemistry with the Shanghai Institute of Medical Materials (SIMM) under China Academy of Sciences.
• Established an OTC R&D organization at Tianjin in 2003.
• Recently, GSK has further boosted its R&D investment in China with an emphasis on cancer prevention and treatment.
• Current main R&D activity is Chemistry, collaboration parterners include Wuxi PharmaTech, Shanghai ChemPartner, Jilin University and Xiaotong University.

The R&D success in China over the last 20 years has encouraged GSK to develop a more comprehensive and robust R&D strategy to develop China into a key strategic center for GSK global R&D.